Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

1.

Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease.

Blin J, Ivanoiu A, De Volder A, Michel C, Bol A, Verellen C, Seron X, Duprez T, Laterre EC.

Psychopharmacology (Berl). 1998 Apr;136(3):256-63.

PMID:
9566811
[PubMed - indexed for MEDLINE]
2.

Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients.

Blin J, Ivanoiu A, Coppens A, De Volder A, Labar D, Michel C, Laterre EC.

Neuroimage. 1997 Nov;6(4):335-43.

PMID:
9417975
[PubMed - indexed for MEDLINE]
3.

Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?

Blin J, Mazetti P, Mazoyer B, Rivaud S, Ben Ayed S, Malapani C, Pillon B, Agid Y.

Brain. 1995 Dec;118 ( Pt 6):1485-95.

PMID:
8595479
[PubMed - indexed for MEDLINE]
4.

Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography.

Blin J, Piercey MF, Giuffra ME, Mouradian MM, Chase TN.

J Neurol Sci. 1994 May;123(1-2):44-51.

PMID:
8064320
[PubMed - indexed for MEDLINE]
5.

PET studies and cholinergic therapy in Alzheimer's disease.

Nordberg A.

Rev Neurol (Paris). 1999;155 Suppl 4:S53-63. Review.

PMID:
10637939
[PubMed - indexed for MEDLINE]
6.

Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.

Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH.

Int J Neuropsychopharmacol. 2001 Sep;4(3):223-30.

PMID:
11602028
[PubMed - indexed for MEDLINE]
7.
8.

Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography.

Blin J, Ray CA, Piercey MF, Bartko JJ, Mouradian MM, Chase TN.

Brain Res. 1994 Jan 28;635(1-2):196-202.

PMID:
8173955
[PubMed - indexed for MEDLINE]
9.

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.

Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM.

Am J Psychiatry. 2002 May;159(5):738-45.

PMID:
11986126
[PubMed - indexed for MEDLINE]
10.

Pharmacological modulation of prefrontal cortical activity during a working memory task in young and older humans: a PET study with physostigmine.

Freo U, Ricciardi E, Pietrini P, Schapiro MB, Rapoport SI, Furey ML.

Am J Psychiatry. 2005 Nov;162(11):2061-70.

PMID:
16263845
[PubMed - indexed for MEDLINE]
11.

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.

Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, DeKosky S, Wester HJ, Schwaiger M, Kurz A.

Neuroimage. 2008 Jan 15;39(2):619-33. Epub 2007 Sep 21.

PMID:
17962045
[PubMed - indexed for MEDLINE]
12.

Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.

Kaasinen V, Någren K, Järvenpää T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO.

J Clin Psychopharmacol. 2002 Dec;22(6):615-20.

PMID:
12454562
[PubMed - indexed for MEDLINE]
13.

Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.

Bentley P, Driver J, Dolan RJ.

Brain. 2008 Feb;131(Pt 2):409-24. Epub 2007 Dec 12.

PMID:
18077465
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging.

Petrie EC, Peskind ER, Dobie DJ, Veith RC, Raskind MA.

Psychoneuroendocrinology. 2001 Feb;26(2):147-64.

PMID:
11087961
[PubMed - indexed for MEDLINE]
15.

Propentofylline enhances cerebral metabolic response to auditory memory stimulation in Alzheimer's disease.

Mielke R, Ghaemi M, Kessler J, Kittner B, Szelies B, Herholz K, Heiss WD.

J Neurol Sci. 1998 Jan 21;154(1):76-82.

PMID:
9543326
[PubMed - indexed for MEDLINE]
16.

Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory.

Bentley P, Driver J, Dolan RJ.

Brain. 2009 Sep;132(Pt 9):2356-71. doi: 10.1093/brain/awp176. Epub 2009 Jul 15.

PMID:
19605530
[PubMed - indexed for MEDLINE]
Free Article
17.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.

Brain. 2006 Nov;129(Pt 11):2856-66. Epub 2006 Jul 19.

PMID:
16854944
[PubMed - indexed for MEDLINE]
Free Article
18.

Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.

Möller H-J, Hampel H, Hegerl U, Schmitt W, Walter K.

Pharmacopsychiatry. 1999 May;32(3):99-106.

PMID:
10463377
[PubMed - indexed for MEDLINE]
19.

Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.

Muramoto O, Sugishita M, Sugita H, Toyokura Y.

Arch Neurol. 1979 Aug;36(8):501-3.

PMID:
508162
[PubMed - indexed for MEDLINE]
20.

Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease.

Berent S, Giordani B, Foster N, Minoshima S, Lajiness-O'Neill R, Koeppe R, Kuhl DE.

J Psychiatr Res. 1999 Jan-Feb;33(1):7-16.

PMID:
10094234
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk